Development of Mucoadhesive Electrospun Scaffolds for Intravaginal Delivery of Spp., a Tenside, and Metronidazole for the Management of Bacterial Vaginosis
Overview
Authors
Affiliations
Bacterial vaginosis (BV) is an infection of the vagina associated with thriving anaerobes, such as and other associated pathogens. These pathogens form a biofilm responsible for the recurrence of infection after antibiotic therapy. The aim of this study was to develop a novel mucoadhesive polyvinyl alcohol and polycaprolactone electrospun nanofibrous scaffolds for vaginal delivery, incorporating metronidazole, a tenside, and . This approach to drug delivery sought to combine an antibiotic for bacterial clearance, a tenside biofilm disruptor, and a lactic acid producer to restore healthy vaginal flora and prevent the recurrence of bacterial vaginosis. F7 and F8 had the least ductility at 29.25% and 28.39%, respectively, and this could be attributed to the clustering of particles that prevented the mobility of the crazes. F2 had the highest at 93.83% due to the addition of a surfactant that increased the affinity of the components. The scaffolds exhibited mucoadhesion between 31.54 ± 0.83% and 57.86 ± 0.95%, where an increased sodium cocoamphoacetate concentration led to increased mucoadhesion. F6 showed the highest mucoadhesion at 57.86 ± 0.95%, as compared to 42.67 ± 1.22% and 50.89 ± 1.01% for the F8 and F7 scaffolds, respectively. The release of metronidazole via a non-Fickian diffusion-release mechanism indicated both swelling and diffusion. The anomalous transport within the drug-release profile pointed to a drug-discharge mechanism that combined both diffusion and erosion. The viability studies showed a growth of in both the polymer blend and the nanofiber formulation that was retained post-storage at 25 °C for 30 days. The developed electrospun scaffolds for the intravaginal delivery of spp., along with a tenside and metronidazole for the management of bacterial vaginosis, provide a novel tool for the treatment and management of recurrent vaginal infection.
Macartney R, Das A, Imaniyyah A, Fricker A, Smith A, Fedele S J Tissue Eng. 2025; 16:20417314241313458.
PMID: 39944725 PMC: 11815840. DOI: 10.1177/20417314241313458.
The Potential of Films as Transmucosal Drug Delivery Systems.
de Carvalho A, Paiva N, Demonari I, Duarte M, do Couto R, de Freitas O Pharmaceutics. 2023; 15(11).
PMID: 38004562 PMC: 10675688. DOI: 10.3390/pharmaceutics15112583.
Rapid-dissolving electrospun nanofibers for intra-vaginal antibiotic or probiotic delivery.
Minooei F, Gilbert N, Zhang L, Sarah NeCamp M, Mahmoud M, Kyser A Eur J Pharm Biopharm. 2023; 190:81-93.
PMID: 37479065 PMC: 10530173. DOI: 10.1016/j.ejpb.2023.07.009.